From Biopsy to Digital Pathology: How Immunohistochemistry Is Evolving Across Asia Pacific
According to a new report by Polaris Market Research, the Asia Pacific immunohistochemistry market was valued at USD 531.20 million in 2024 and is projected to reach USD 1,218.85 million by 2034, expanding at a CAGR of 8.7% over the forecast period. Growth is underpinned by the rising prevalence of chronic disease, expanding adoption of personalized medicine, and accelerating investment in diagnostic infrastructure across key end-use industries.
What Is Driving Asia Pacific Immunohistochemistry Market Growth?
Demand is climbing as the region's growing chronic disease burden converges with rising healthcare expenditure across China, India, and Australia. Manufacturers and clinical laboratories are prioritizing precise, tissue-based biomarker detection, pushing immunohistochemistry (IHC) adoption deeper into oncology, infectious disease screening, and companion diagnostics. Polaris analysts note that cancer incidence in Asia stood at 169.1 per 100,000 people in 2020, accounting for roughly half of the global cancer burden, positioning the segment for sustained double-digit growth through 2034, with hospitals and diagnostic laboratories emerging as the largest revenue contributor and the kits segment posting the fastest incremental gains.
Key Trends Shaping the Asia Pacific Immunohistochemistry Industry
Rising Geriatric Population
Older adults face elevated risk of cancer, neurodegenerative disorders, and cardiovascular disease, all of which rely on detailed tissue diagnostics. The United Nations Population Fund projects India's 80+ population will grow roughly 279% between 2022 and 2050, a demographic shift that is steadily lifting demand for IHC-based disease characterization across regional clinical labs.
Increasing Product Development and Launches
Companies across the region are introducing advanced antibodies, automated staining systems, and multiplex assays that improve the speed and reproducibility of IHC workflows. Multiplex platforms in particular allow simultaneous detection of multiple biomarkers, supporting more comprehensive disease profiling and broader adoption in both clinical and research settings.
Regulatory Momentum in Companion Diagnostics
Recent regulatory clearances are reinforcing the technology's role in precision oncology. In August 2025, Agilent secured US FDA approval for its MMR IHC Panel pharmDx as a companion diagnostic identifying dMMR colorectal cancer patients eligible for targeted immunotherapy, while Roche obtained approval in May 2025 for an assay that enables patient selection for a targeted NSCLC therapy — both signaling an outlook of tighter integration between IHC testing and treatment decisions.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-immunohistochemistry-market
Market Segmentation: Breaking Down the Asia Pacific Immunohistochemistry Market
Polaris segments the Asia Pacific immunohistochemistry market by product, application, end use, and country, giving each buyer persona a standalone, citable data point.
By Product
The antibodies segment led the market in 2024, supported by its central role in detecting and analyzing cellular proteins for cancer diagnostics across China, Japan, and India. The kits segment is projected to expand at the fastest pace through 2034 as standardized, ready-to-use formats simplify complex staining procedures and support high-throughput cancer diagnostics.
By End Use
Hospitals and diagnostic laboratories accounted for the largest revenue share in 2024, driven by rising cancer prevalence and continued investment in advanced diagnostic tools and trained pathology personnel. Research institutes continue to represent a meaningful and growing share as academic and translational research expands across the region.
By Country
China led the market in 2024 on the strength of a rapidly expanding healthcare system, substantial government investment in cancer research, and the Healthy China 2030 initiative. India is projected to grow at the fastest pace, propelled by its expanding population, rising cancer burden, and government-backed programs such as Ayushman Bharat and Make in India that are strengthening domestic diagnostic infrastructure.
Regional Outlook: Where Is the Immunohistochemistry Market Growing Fastest?
China led the Asia Pacific market in 2024 on the back of expanding healthcare infrastructure and a strong domestic biotechnology sector, while India is expected to post the fastest CAGR through 2034, driven by rising cancer awareness and expanding public and private healthcare access. Japan and Australia round out the region's other significant markets, supported by established diagnostic infrastructure and steady research funding.
Competitive Landscape: Leading Asia Pacific Immunohistochemistry Companies
Key players profiled in the report include Agilent Technologies, Inc., Cell Signaling Technology, Inc., Thermo Fisher Scientific Inc., Roche Ltd., and Merck KGaA, among others, who are focusing on automation, novel biomarker development, and strategic partnerships to strengthen market position across the antibodies and hospital diagnostics segments outlined above. Recent moves include Agilent's FDA companion-diagnostic approval and Roche's VENTANA MET RxDx Assay clearance, both aimed at deepening share in precision oncology across the region.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching the Asia Pacific immunohistochemistry market, this report benchmarks market share, segment-level pricing, and forecast data — by product, application, end use, and country — to support sourcing, investment, and go-to-market decisions. It is built for procurement teams comparing suppliers, investors sizing entry points, and strategy teams tracking multiplex assays as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research and consulting firm offering 5,000+ published reports across 20+ industry verticals, delivering data-backed insights to help businesses make informed decisions.
More Trending Latest Reports By Polaris Market Research:
The Secret Printing Technology Taking the Market by Storm - Microprinting
Power Management Integrated Circuits Market
- Asia_Pacific_Immunohistochemistry_Market_Forecast
- Asia_Pacific_Immunohistochemistry_Market_Growth
- Asia_Pacific_Immunohistochemistry_Market_Industry
- Asia_Pacific_Immunohistochemistry_Market_Key_Players
- Asia_Pacific_Immunohistochemistry_Market_Opportunity
- Asia_Pacific_Immunohistochemistry_Market_Report
- Asia_Pacific_Immunohistochemistry_Market_Research
- Asia_Pacific_Immunohistochemistry_Market_Scope
- Asia_Pacific_Immunohistochemistry_Market_Share
- Asia_Pacific_Immunohistochemistry_Market_Size
- Asia_Pacific_Immunohistochemistry_Market_Technology
- Asia_Pacific_Immunohistochemistry_Market_Trends
- Asia_Pacific_Immunohistochemistry_Market_United_Kingdom
- Asia_Pacific_Immunohistochemistry
- Asia_Pacific_Immunohistochemistry_Market
- Asia_Pacific_Immunohistochemistry_Market_Analysis
- Asia_Pacific_Immunohistochemistry_Market_CAGR
- Art
- Causes
- Crafts
- Dance
- Drinks
- Film
- Fitness
- Food
- الألعاب
- Gardening
- Health
- الرئيسية
- Literature
- Music
- Networking
- أخرى
- Party
- Religion
- Shopping
- Sports
- Theater
- Wellness